Current Report Filing (8-k)
October 29 2019 - 1:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): Monday, October 28, 2019
Generex
biotechnology corpORATION
(Exact of registrant as specified in
its charter)
DELAWARE
|
000-29169
|
98-0178636
|
State or other jurisdiction of incorporation
|
Commission File Number
|
IRS Employer Identification №.
|
10102 USA Today Way, Miramar, Florida
|
33025
|
(Address of principal executive offices)
|
(Zip Code)
|
(416) 364-2551
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[_] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter) ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13 (a) of the Exchange Act. ¨
Item 8 – Other Events
Generex and its subsidiaries, NuGenerex Distribution
Solutions, LLC and NuGenerex Distributions Solutions 2, LLC (jointly “NDS”) filed an arbitration action against Veneto
Holdings, LLC and certain affiliated entities holding shares of our common stock issued in connection with our acquisition of Veneto’s
assets, alleging, among other things, that Veneto never transferred the ownership rights in at least one pharmacy to NDS.
This pharmacy was a necessary element in the operation of other assets transferred by Veneto. The ownership rights in this pharmacy
was a substantial portion of the consideration for shares issued to Veneto and its affiliates, and, as a result, Generex contends
the shares issued to Veneto and its affiliates were never fully paid for. The arbitration is pending before the American Arbitration
Association in Delaware.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 29, 2019
Generex Biotechnology Corp.
/s/ Joe
Moscato
By: Joe Moscato, CEO, President
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Apr 2023 to Apr 2024